Should my family be tested?

When one person in a family is diagnosed with Wilson disease, first-degree relatives are at meaningful risk of also carrying the condition. Wilson disease is autosomal recessive, meaning a person inherits one faulty copy of the ATP7B gene from each parent.¹ That inheritance pattern gives siblings a one-in-four (25%) chance of having the disease, and children a risk that depends on whether the other parent carries a mutation.²

Many of these relatives will be pre-symptomatic — already accumulating copper, but not yet showing any clinical signs. This is one of the rare situations in medicine where screening before symptoms appear can spare a person an entire disease course. Both the American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver (EASL) strongly recommend that all first-degree relatives of a diagnosed patient be evaluated.³⁴

Who to test

Relative	Approximate risk	Priority
Siblings	25% (1 in 4)	Highest
Children	Depends on partner carrier status	High
Parents	Almost always healthy carriers	Confirm status

How they are tested

Two complementary approaches are used together:

1. Genetic testing — once the index patient’s specific ATP7B mutations are identified, relatives can be tested directly for those same variants. This approach is fast, definitive, and has become the modern standard for family evaluation, with biochemical methods now playing a confirmatory rather than primary role.³⁵

2. Biochemical screening — ceruloplasmin, serum copper, 24-hour urinary copper, slit-lamp eye examination, and liver enzymes. These tests are added when genetic results are unavailable, ambiguous, or to characterise liver status in a relative who tests positive genetically.⁴

Genetic and biochemical results should be interpreted together by a clinician experienced in Wilson disease, because neither test is perfect in isolation.³

What if a relative tests positive?

A pre-symptomatic relative with two ATP7B mutations should:

• Be referred to a hepatologist familiar with Wilson disease
• Begin lifelong copper-lowering therapy — zinc salts are commonly used in this setting because the liver has not yet sustained established copper overload, though the choice of agent is an individual clinical decision⁶
• Begin standard monitoring (liver enzymes, urinary copper, periodic slit-lamp exam)

Pre-symptomatic patients who start treatment can expect a normal or near-normal life span, with organ damage largely prevented.⁷ Early detection genuinely changes the trajectory of the disease — and family screening is how that early detection happens.³

What if a relative is a carrier (one mutation only)?

Carriers — people who have inherited only one abnormal copy of ATP7B — do not have Wilson disease and do not need treatment.³ Their liver copper metabolism is entirely normal. What matters is that they know their status for future reproductive planning: if both partners in a couple are carriers, each pregnancy carries a 25% chance of producing a child with Wilson disease.²

Practical advice

• Ask your hepatologist for a brief written summary of your mutations and test results that relatives can take to their own doctor. Many physicians outside specialist centres are unfamiliar with Wilson disease, and this avoids weeks of confusion.
• In regions where Wilson disease is rarely seen, bringing a copy of the AASLD 2022 Practice Guidance³ or the EASL Clinical Practice Guidelines⁴ to share with the relative’s physician can be genuinely helpful.
• Genetic testing of relatives is typically straightforward once the index patient’s mutations are confirmed — it is often a single blood draw.

This post is for patient education only and is not a substitute for individualised medical advice. Please discuss screening and testing decisions with your own physician or specialist.

References